An efficient and selective in vitro solid phase assay for PCSK4 activity: Potential diagnostic tool in fetal and placental growth restriction Caroline Muia, Chunyu Lu and Dr.Ajoy Basak Health Science Department, University of Ottawa Introduction Methods Nearly half of all infant mortality occur in the first 28 days after birth with Intrauterine Growth Restriction (IUGR) syndrome being one of the leading causes. Even today despite advancements in research and our better understanding of the mechanism of this condition, it still remains in the forefront of reproduction research. IUGR, also called Fetal Restricted Syndrome (FRS), leads to abnormal development and growth of placenta and fetus. It is linked to the proteolytic activity of PCSK4 (Proprotein Convertase Subtilisin/Kexin type 4) enzyme, also known as PC4. This enzyme is exclusively present in reproductive tissues/organs including ovary and placenta. It is present on the surface of plasma membrane overlying the acrosome of the sperm. It cleaves inactive larger pro-Insulin growth factor2 (proIGF2) to generate its mature shorter form IGF2, which plays a crucial role in fetal and placental growth/ development during pregnancy. Decreased PCSK4 activity leads to less production of mature IGF2 causing IUGR condition. Thus monitoring PCSK4 activity using a selective and sensitive method will be useful for early detection of IUGR. Design & Preparation of a fluorescent peptide: A 5-amino acid long peptide sequence mimicking the recognition motif of PCSK4 enzyme was selected from the cleavage site of proIGF2 (human) which is described as the most potent physiological substrate of PCSK4. -The above peptide also contains a linker (Adoa) and Cys-attached Fluorescence moiety as shown below. -The peptide thus designed was synthesized using Solid Phase Peptide Chemistry using Intavis MultiPep instrument and PEGA resin on which the it remain immobilized. Fluorescent & non-fluorescent PEGA resins under microscope Fluorescent resin (fluorescent filter) Fluorescent resin Non-fluorescent resin MS of supernatants showing fragments after enzyme digestion & control + Water (Control) Enzyme assay: The above immobilized fluorescent peptide on resin (~100 mg) was incubated with various enzymes including recombinant PCSK4 available in the lab Intensity Fluorescent group 0 PCSK4 cleavage site 1000 2000 50 Caroline- 25 0 Linker -Cys- 0 0 Linker 1000 1000 2000 2000 +PCSK4 15 N S D H D 637 S mPC2/PCSK2 D H N RESULTS 814 ykexin S PCSK4 cleavage site Fluorescent group 654 753 rPC4A/PCSK4 D H N S Linker 783 N S Lys-Ser-Glu-Arg -Cys- mPC1/PCSK1 D H 25 Linker Asp 20 15 N Resin 1877 S - Aqueous sample containing active PC4 - Incubate at 40C for 3 - 4 hours rPC5A/PCSK5 969 rPC5B 1052 D H N S 692 C-terminal piece hPACE4A/PCSK6 D H D H N N N-terminal piece S hSKI-1/PCSK8 S Signal peptide P-domain Cytoplasmic GF/cytokine receptor Pro-segment Ser/Thr rich Amphipathic RGD(S) sequence Trans membrane Cys-rich domain N-glycosylation Catalytic domain Asp Lys-Ser-Glu-Arg -Cys- hNARC1/PCSK9 12.5 1460.5 1302.8 731 (Dye) 10 7.5 1000 1000 2000 2000 1500 1500 1000 1500 1500 2500 2500 200 200 m/z m/z + Pepsin 915 + Chymotrypsin 1500 2000 1464.8 3000 2500 1306.7 Intensity N 1314.6? 731 (Dye) 928.3? 1000 1000 hfurin/PCSK3 D H 200 1712.9 965.7? 5 794 S 1464.8 (4) 10 rPC7/PCSK7 D H 2155 0 0 00 1088.7 1100.2 (1) Intensity 382 D H 2000 1000 Intensity Subtilisin 1500 30 Amino acids S 4000 4000 + Trypsin Intensity N 3000 3000 m/z Resin Adoa - Lys-Ser-Glu-Arg-Asp - Adoa Adoa=8-Amino 3,6-Dioxa-Octanoic acid), serves as an 8-atom linker/spacer chain D H 4000 365.2 (Matrix) 75 1000 Enzyme 3000 40 30 1183.0 1522.4 20 Resin 1100.2 Car 10 1000 1000 C-terminal N-terminal highly fluorescent fragment (Supernatant) 1500 1500 2000 2000 +Endo-Lysine-C 1000 2000 3000 750 Decreased level or impaired PCSK4 protease activity is responsible for production of low mature IGF2 level leading to IUGR. Cleavage by Proteases Intensity 1093.8 (1) Hypothesis 30 Objective 1250 5000 1500 30 1117.7 (M+Na) Caroline-Mar07-201 Car 20 20 10 750 750 2000 2000 1000 1000 3000 3000 1250 1250 4000 4000 1500 1500 5000 5000 m/z S CH2 H2N-Cys-Adoa-Lys-Ser-OH Summary MW 1198 - A novel solid phase fluorescence based method has been developed for in vitro assay of PCSK4 activity Develop an efficient, highly selective and rapid solid phase fluorescence based method for monitoring PCSK4 protease activity in vitro. S CH2 H2N-Cys-Adoa-Lys-Ser-Glu-OH 1 Aim 1: Design and Synthesis of a Highly Flourescent Peptide 4000 1093.8 (M) 40 1000 1000 MW 1111 1000 40 10 S CH2 H2N-Cys-Adoa-Lys-OH 3000 3000 m/z m/z C-terminal non fluorescent fragment + undigested peptide (Resin) All possible cleavages and the expected Mol Wts of all fragments thus produced and released into the medium (supernatant). 2500 2500 2 3 4 5 MW 1327 S CH2 H2N-Cys-Adoa-Lys-Ser-Glu-Arg-Asp-Adoa- PEGA-Resin - The method is very simple and can be made selective and sensitive by using dextro amino acid incorporation and the use of protease inhibitors - Application of this method for examination of PCSK4 activity in Placenta tissue is under progress. MW 1733 Acknowledgement Aim 2: Application of the Fluorescent Peptide for selective In Vitro Assay of PCSK4 Activity I thank Chunyu Lu for his skilled technical assistance as well as other lab members. Thanks are also due to the University of Ottawa for the award of UROP fellowship and Dr. Ajoy Basak for his guidance, supervision and the opportunity to work in his laboratory. Aim 3: Potential Application of the above method for monitoring PCSK4 activity in biological samples under IUGR vs Control conditions S CH2 H2N-Cys-Adoa-Lys-Ser-Glu-Arg-Asp-OH MW 1598 S CH2 H2N-Cys-Adoa-Lys-Ser-Glu-Arg-OH MW 1483 References Qiu et al PNAS, 102, 11047-52, 2005; DeChiara et al Cell 64, 849-59, 1991; Baker, J. et al Cell 75, 73-82, 1993; Constancia, M. et al Nature 417, 945-48, 2002; Fowden, A. L. Placenta 24, 803-12, 2003; Saving Lives at Birth: A Grand Challenge for Development, Grand Challenge Development, 2014; Basak et al Methods in Molecular Biology 768
© Copyright 2024 ExpyDoc